NO952184L - Törrblandeformulering for bisfosfonsyrer - Google Patents

Törrblandeformulering for bisfosfonsyrer

Info

Publication number
NO952184L
NO952184L NO952184A NO952184A NO952184L NO 952184 L NO952184 L NO 952184L NO 952184 A NO952184 A NO 952184A NO 952184 A NO952184 A NO 952184A NO 952184 L NO952184 L NO 952184L
Authority
NO
Norway
Prior art keywords
bisphosphonic acid
stearate
amino
lactose
hydroxybutylidene
Prior art date
Application number
NO952184A
Other languages
English (en)
Other versions
NO308986B1 (no
NO952184D0 (no
NO308986B3 (no
Inventor
Simon R Bechard
Kenneth A Kramer
Ashok V Katdare
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25530524&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO952184(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO952184L publication Critical patent/NO952184L/no
Publication of NO952184D0 publication Critical patent/NO952184D0/no
Publication of NO308986B1 publication Critical patent/NO308986B1/no
Publication of NO308986B3 publication Critical patent/NO308986B3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
NO19952184A 1992-12-02 1995-06-01 Fremgangsmate for fremstilling av en tablett inneholdende som aktiv bestanddel et basisk nitrogenholdig bisfosfonat og farmasoytisk preparat NO308986B3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/984,399 US5358941A (en) 1992-12-02 1992-12-02 Dry mix formulation for bisphosphonic acids with lactose
PCT/US1993/011172 WO1994012200A1 (en) 1992-12-02 1993-11-17 Dry mix formulation for bisphosphonic acids

Publications (4)

Publication Number Publication Date
NO952184L true NO952184L (no) 1995-06-01
NO952184D0 NO952184D0 (no) 1995-06-01
NO308986B1 NO308986B1 (no) 2000-11-27
NO308986B3 NO308986B3 (no) 2000-11-27

Family

ID=25530524

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19952184A NO308986B3 (no) 1992-12-02 1995-06-01 Fremgangsmate for fremstilling av en tablett inneholdende som aktiv bestanddel et basisk nitrogenholdig bisfosfonat og farmasoytisk preparat

Country Status (32)

Country Link
US (5) US5358941A (no)
EP (2) EP1051975A1 (no)
JP (3) JP3365634B2 (no)
KR (2) KR100286063B1 (no)
CN (3) CN1066624C (no)
AT (1) ATE196736T1 (no)
AU (1) AU677264C (no)
BG (1) BG62795B1 (no)
CA (1) CA2149052C (no)
CY (1) CY2236B1 (no)
CZ (2) CZ289966B6 (no)
DE (1) DE69329533T2 (no)
DK (1) DK0690719T3 (no)
ES (1) ES2150979T3 (no)
FI (1) FI113839B (no)
GR (1) GR3034936T3 (no)
HK (1) HK1009252A1 (no)
HU (1) HU220604B1 (no)
IL (1) IL107741A (no)
LV (1) LV12715B (no)
MX (1) MX9307569A (no)
NO (1) NO308986B3 (no)
NZ (1) NZ258442A (no)
PL (1) PL309245A1 (no)
PT (1) PT690719E (no)
RO (1) RO113429B1 (no)
RU (1) RU2148405C1 (no)
SK (1) SK282100B6 (no)
TW (1) TW422707B (no)
UA (1) UA46701C2 (no)
WO (1) WO1994012200A1 (no)
ZA (1) ZA938979B (no)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096342A (en) 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
DE69231313T2 (de) * 1991-11-22 2001-03-15 Procter & Gamble Pharma Risedronat enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
GB2295966B (en) * 1994-12-14 1997-09-24 Bioglan Ireland Direct compression tablets
AU713824B2 (en) * 1995-05-12 1999-12-09 Merck Sharp & Dohme Corp. Prevention of tooth loss by the administration of alendronate or its salts
CA2221844A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations
WO1996039149A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
NZ334836A (en) * 1996-10-04 2000-11-24 Merck & Co Inc Liquid alendronate formulations and their use in preventing bone resorption
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
CN1274279A (zh) * 1997-06-11 2000-11-22 普罗克特和甘保尔公司 能改进胃肠道上部安全性的膜包衣片剂
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
IL121623A (en) 1997-08-26 2000-06-29 Unipharm Ltd Process for the preparation of solid oral dosage forms comprising alendronic acid
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
US8586781B2 (en) * 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US7598246B2 (en) 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6750340B2 (en) 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
CN1237958C (zh) 1998-06-11 2006-01-25 法玛西雅厄普约翰美国公司 一种非缓释的、非咀嚼的药物片剂组合物
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6984400B2 (en) * 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
PT1178810E (pt) * 1999-05-21 2005-08-31 Novartis Ag Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese
AR024462A1 (es) * 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
PL196485B1 (pl) * 2000-05-11 2008-01-31 Inst Farmaceutyczny Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
CZ20002567A3 (cs) 2000-07-11 2001-12-12 Léčiva, A.S. Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
US6638920B2 (en) 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US7964216B2 (en) * 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
PT1377276E (pt) * 2001-04-10 2011-12-30 Sun Pharma Advanced Res Co Ltd Composição de libertação temporizada por pulso
WO2002087546A2 (en) * 2001-05-01 2002-11-07 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
SK2532004A3 (en) * 2001-12-21 2004-11-03 Procter & Gamble Method for the treatment of bone disorders
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
CA2470495A1 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
AU2003233569A1 (en) * 2002-05-17 2003-12-02 Teva Pharmaceutical Industries Ltd. Use of certain diluents for making bisphosphonic acids
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
RU2315603C2 (ru) * 2002-12-20 2008-01-27 Ф.Хоффманн-Ля Рош Аг Композиция с высокой дозой ибандроната
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
EP2213661B1 (en) 2003-09-26 2011-07-20 Exelixis Inc. c-Met Modulators and Methods of Use
WO2005030177A2 (en) * 2003-09-29 2005-04-07 Cipla Limited Pharmaceutical formulation with improved stability
US6783772B1 (en) * 2003-12-12 2004-08-31 Sanjeev Khandelwal Pharmaceutical preparations containing alendronate sodium
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
BRPI0606283A2 (pt) * 2005-03-16 2009-06-09 Elan Pharma Int Ltd formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
JP2008533173A (ja) * 2005-03-17 2008-08-21 エラン ファーマ インターナショナル リミテッド ナノ粒子ビスホスホネート組成物
CA2611475A1 (en) * 2005-06-09 2006-12-21 Elan Pharma International, Limited Nanoparticulate ebastine formulations
EA015687B1 (ru) 2006-05-04 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2008020305A2 (en) * 2006-08-17 2008-02-21 Aurobindo Pharma Limited Solid dosage forms of bisphosphonic acids
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
MX2009001271A (es) * 2006-11-21 2009-02-11 Teikoku Pharma Usa Inc Formulaciones inhalantes de bisfosfonato y metodos para el uso de las mismas.
CA2671727C (en) * 2006-12-20 2016-02-16 Genpharm Ulc A composition containing a bisphosphonic acid in combination with vitamin d
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
UA102582C2 (en) 2009-05-19 2013-07-25 Селджин Корпорейшн Oral dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
TW201309650A (zh) 2011-02-10 2013-03-01 Exelixis Inc 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
US20130164376A1 (en) * 2011-12-27 2013-06-27 Celgene Corporation Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
HRP20230265T1 (hr) 2014-08-22 2023-04-14 Celgene Corporation Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima
EP2992885A3 (en) 2014-09-02 2016-05-18 Jansfat Biotechnology Co., Ltd. Method for inhibiting a liver disease
US20170312286A1 (en) 2016-05-02 2017-11-02 Jansfat Biotechnology Co., Ltd. Compositions and methods for lipid metabolism disorder
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1036368A (en) * 1963-10-31 1966-07-20 Nat Dairy Prod Corp Method for the manufacture of lactose-containing tablets
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
DE3767998D1 (de) * 1986-12-20 1991-03-14 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JP2525478B2 (ja) * 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
US5070108A (en) * 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose

Also Published As

Publication number Publication date
EP0690719A4 (no) 1996-01-24
BG99663A (bg) 1996-02-28
PL309245A1 (en) 1995-10-02
KR950703985A (ko) 1995-11-17
BG62795B1 (bg) 2000-08-31
JPH08506092A (ja) 1996-07-02
CA2149052A1 (en) 1994-06-09
NO308986B1 (no) 2000-11-27
US5882656A (en) 1999-03-16
ZA938979B (en) 1994-08-03
WO1994012200A1 (en) 1994-06-09
NZ258442A (en) 1996-12-20
RO113429B1 (ro) 1998-07-30
FI952685A0 (fi) 1995-06-01
CN1066624C (zh) 2001-06-06
AU5611594A (en) 1994-06-22
CZ290197B6 (cs) 2002-06-12
US6194004B1 (en) 2001-02-27
TW422707B (en) 2001-02-21
US5681590A (en) 1997-10-28
SK282100B6 (sk) 2001-11-06
HUT72645A (en) 1996-05-28
ATE196736T1 (de) 2000-10-15
KR20030096426A (ko) 2003-12-31
CZ134695A3 (en) 1995-10-18
CA2149052C (en) 2003-03-25
AU677264B2 (en) 1997-04-17
FI952685A (fi) 1995-06-01
NO952184D0 (no) 1995-06-01
IL107741A0 (en) 1994-02-27
JP2002348241A (ja) 2002-12-04
DE69329533D1 (de) 2000-11-09
US6090410A (en) 2000-07-18
AU677264C (en) 2005-09-29
EP1051975A1 (en) 2000-11-15
GR3034936T3 (en) 2001-02-28
DE69329533T2 (de) 2001-05-31
MX9307569A (es) 1995-01-31
US5358941A (en) 1994-10-25
LV12715A (lv) 2001-09-20
NO308986B3 (no) 2000-11-27
PT690719E (pt) 2001-02-28
CY2236B1 (en) 2003-07-04
JP3854187B2 (ja) 2006-12-06
CZ289966B6 (cs) 2002-05-15
RU2148405C1 (ru) 2000-05-10
CN1554349A (zh) 2004-12-15
JP3365634B2 (ja) 2003-01-14
SK73195A3 (en) 1995-12-06
DK0690719T3 (da) 2000-12-18
KR100473750B1 (ko) 2005-03-07
CN1098907A (zh) 1995-02-22
CN1160076C (zh) 2004-08-04
EP0690719B1 (en) 2000-10-04
UA46701C2 (uk) 2002-06-17
KR100286063B1 (ko) 2001-05-02
IL107741A (en) 1997-06-10
FI113839B (fi) 2004-06-30
EP0690719A1 (en) 1996-01-10
CN1233468A (zh) 1999-11-03
JP2003073277A (ja) 2003-03-12
HK1009252A1 (en) 1999-05-28
JP4267877B2 (ja) 2009-05-27
HU220604B1 (hu) 2002-03-28
HU9501590D0 (en) 1995-08-28
LV12715B (en) 2001-12-20
ES2150979T3 (es) 2000-12-16

Similar Documents

Publication Publication Date Title
NO952184L (no) Törrblandeformulering for bisfosfonsyrer
WO1996014365A3 (en) Process for stabilizing gelatin products
DE3862272D1 (de) Etodolac mit anhaltender freigabe.
CA2301185A1 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
SI8710406B (sl) Tablete s podaljšanim delovanjem na osnovi hidroksipropilmetilceluloze z veliko molsko maso in postopek za njihovo pripravo
JPS5940147B2 (ja) プロスタグランジン含有凍結乾燥粉末、その製法及び医薬及び獣医薬組成物
AU8221291A (en) Cyclopentane derivatives, process for producing them and their pharmaceutical use
ES458967A1 (es) Un procedimiento para la preparacion de una composicion de prostaglandina estabilizada.
CA2199155A1 (en) Process for stabilizing gelatin products
JP3008297B2 (ja) カフェインウィスカー抑制錠
KR910009287A (ko) 활성 화합물의 방출이 지연되지 않는 압착물, 이의 제조방법 및 이러한 압착물 제조용 폴리하이드록시부티르산의 용도
GB1512594A (en) 15-ethynyl prostaglandins
RU95106669A (ru) Гемфиброзилсодержащие фармацевтические композиции
AU1563102A (en) Sustained-release prostaglandin I derivative preparation

Legal Events

Date Code Title Description
LC4 Limitation of patent rights - b3 (par. 39b patent act)